{"transactions":[{"id":934508,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-01-21T21:49:30.000Z","date":"2026-01-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2026."}],"balance_after":60000,"derivative":{"exercise_price":3.04,"expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-26-000036","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000036/form4.xml","form_type":"4"}},{"id":959971,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T18:21:11.000Z","date":"2025-12-23","kind":"purchase","planned":false,"acquired":true,"shares":5500,"price":3.548,"value":19514.0,"ownership":{"direct":true},"balance_after":55269,"source":{"system":"sec-edgar","filing":"0001133416-25-000081","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000081/form4a.xml","form_type":"4/A","original_submission_date":"2025-12-23"}},{"id":959970,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T18:19:30.000Z","date":"2025-12-23","kind":"purchase","planned":true,"acquired":true,"shares":5500,"price":3.548,"value":19514.0,"ownership":{"direct":true},"balance_after":55269,"source":{"system":"sec-edgar","filing":"0001133416-25-000080","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000080/form4a.xml","form_type":"4/A","original_submission_date":"2025-12-23"}},{"id":959968,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T16:29:19.000Z","date":"2025-12-23","kind":"purchase","planned":true,"acquired":true,"shares":5500,"price":3.548,"value":19514.0,"ownership":{"direct":true},"balance_after":55269,"source":{"system":"sec-edgar","filing":"0001133416-25-000075","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000075/form4.xml","form_type":"4"}},{"id":1084861,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-07-18T14:38:28.000Z","date":"2025-07-17","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":2.899,"value":14495.0,"ownership":{"direct":true},"balance_after":49769,"source":{"system":"sec-edgar","filing":"0001133416-25-000033","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000033/form4.xml","form_type":"4"}},{"id":1294682,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-01-27T21:04:57.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2025."}],"balance_after":60000,"derivative":{"exercise_price":1.23,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-25-000010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000010/form4.xml","form_type":"4"}},{"id":1322061,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-12-26T13:02:04.000Z","date":"2024-12-24","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.8134,"value":8134.0,"ownership":{"direct":true},"balance_after":44769,"source":{"system":"sec-edgar","filing":"0001133416-24-000062","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000062/form4.xml","form_type":"4"}},{"id":1385118,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-10-17T20:03:23.000Z","date":"2024-10-17","kind":"purchase","planned":false,"acquired":true,"shares":1300,"price":2.64,"value":3432.0,"ownership":{"direct":true},"balance_after":34769,"source":{"system":"sec-edgar","filing":"0001133416-24-000058","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000058/form4.xml","form_type":"4"}},{"id":1386117,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-10-16T20:12:20.000Z","date":"2024-10-16","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":2.7,"value":13500.0,"ownership":{"direct":false,"nature":"By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":80000,"source":{"system":"sec-edgar","filing":"0001133416-24-000056","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000056/form4.xml","form_type":"4"}},{"id":1386116,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-10-16T20:12:20.000Z","date":"2024-10-16","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":2.7,"value":13500.0,"ownership":{"direct":true},"balance_after":33469,"source":{"system":"sec-edgar","filing":"0001133416-24-000056","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000056/form4.xml","form_type":"4"}},{"id":1473564,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-20T17:55:08.000Z","date":"2024-06-20","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":2.3799,"value":5949.75,"ownership":{"direct":true},"balance_after":28469,"source":{"system":"sec-edgar","filing":"0001133416-24-000044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000044/form4.xml","form_type":"4"}},{"id":1537906,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-04-22T20:04:45.000Z","date":"2024-04-22","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":2.98,"value":7450.0,"ownership":{"direct":true},"balance_after":25969,"source":{"system":"sec-edgar","filing":"0001133416-24-000038","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000038/form4.xml","form_type":"4"}},{"id":1544729,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-04-09T20:42:27.000Z","date":"2024-04-09","kind":"other","planned":false,"acquired":true,"shares":2063,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"IRA"},"balance_after":18063,"source":{"system":"sec-edgar","filing":"0001133416-24-000036","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000036/form4.xml","form_type":"4"}},{"id":1655582,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2024-02-07T21:47:36.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2024."}],"balance_after":50000,"derivative":{"exercise_price":1.72,"expiration_date":"2034-01-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001133416-24-000016","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000016/form4.xml","form_type":"4"}},{"id":2042455,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-01-30T21:42:46.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2023."}],"balance_after":40000,"derivative":{"exercise_price":1.11,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001133416-23-000022","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000022/form4.xml","form_type":"4"}},{"id":2129817,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-10-31T13:47:17.000Z","date":"2022-10-28","kind":"purchase","acquired":true,"shares":10000,"price":1.41,"value":14100.0,"ownership":{"direct":false,"nature":"By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":75000,"source":{"system":"sec-edgar","filing":"0001133416-22-000093","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000093/form4.xml","form_type":"4"}},{"id":2262285,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-05-20T11:30:02.000Z","date":"2022-05-19","kind":"purchase","acquired":true,"shares":5000,"price":1.3299,"value":6649.5,"ownership":{"direct":false,"nature":"By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":65000,"source":{"system":"sec-edgar","filing":"0001133416-22-000063","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000063/form4.xml","form_type":"4"}},{"id":2295823,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-04-18T19:59:53.000Z","date":"2022-04-18","kind":"purchase","acquired":true,"shares":5000,"price":1.71,"value":8550.0,"ownership":{"direct":false,"nature":"By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001133416-22-000057","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000057/form4.xml","form_type":"4"}},{"id":2426931,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2022-01-25T21:24:41.000Z","date":"2022-01-24","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2022."}],"balance_after":40000,"derivative":{"exercise_price":1.98,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001133416-22-000022","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000022/form4.xml","form_type":"4"}},{"id":2432657,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-01-19T16:18:30.000Z","date":"2022-01-19","kind":"purchase","acquired":true,"shares":5000,"price":1.9612,"value":9806.0,"ownership":{"direct":false,"nature":"By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":55000,"source":{"system":"sec-edgar","filing":"0001133416-22-000010","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000010/form4.xml","form_type":"4/A","original_submission_date":"2022-01-19"}},{"id":2432658,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-01-19T16:02:44.000Z","date":"2022-01-19","kind":"purchase","acquired":true,"shares":5000,"price":1.9612,"value":9806.0,"ownership":{"direct":false,"nature":"By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001133416-22-000008","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000008/form4.xml","form_type":"4"}},{"id":2472015,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-12-15T21:34:24.000Z","date":"2021-12-15","kind":"purchase","acquired":true,"shares":5000,"price":2.28,"value":11400.0,"ownership":{"direct":false,"nature":"By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001133416-21-000027","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341621000027/form4.xml","form_type":"4/A","original_submission_date":"2021-12-15"}},{"id":2472014,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-12-15T21:25:30.000Z","date":"2021-12-06","kind":"purchase","acquired":true,"shares":5000,"price":2.28,"value":11400.0,"ownership":{"direct":false,"nature":"By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001133416-21-000025","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341621000025/form4.xml","form_type":"4"}},{"id":2484099,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-12-06T19:09:52.000Z","date":"2021-12-06","kind":"purchase","acquired":true,"shares":5000,"price":2.34,"value":11700.0,"ownership":{"direct":false,"nature":"By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":45000,"source":{"system":"sec-edgar","filing":"0001133416-21-000023","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341621000023/form4.xml","form_type":"4"}},{"id":2530917,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-11-01T16:51:05.000Z","date":"2021-10-29","kind":"purchase","acquired":true,"shares":2000,"price":3.17,"value":6340.0,"ownership":{"direct":false,"nature":"By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001133416-21-000017","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341621000017/form4.xml","form_type":"4"}},{"id":2537506,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-10-21T16:52:37.000Z","date":"2021-10-21","kind":"purchase","acquired":true,"shares":2000,"price":3.19,"value":6380.0,"ownership":{"direct":false,"nature":"By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":38000,"source":{"system":"sec-edgar","filing":"0001133416-21-000013","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341621000013/form4.xml","form_type":"4"}},{"id":2539641,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-10-19T18:14:29.000Z","date":"2021-10-19","kind":"purchase","acquired":true,"shares":3000,"price":3.3689,"value":10106.7,"ownership":{"direct":false,"nature":"By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":36000,"source":{"system":"sec-edgar","filing":"0001133416-21-000011","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341621000011/form4.xml","form_type":"4"}},{"id":2561174,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-09-23T20:14:52.000Z","date":"2021-09-23","kind":"purchase","acquired":true,"shares":3000,"price":3.877,"value":11631.0,"ownership":{"direct":false,"nature":"By a limited liability company controlled by the Reporting Person: Freeman Global Holdings, LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":33000,"source":{"system":"sec-edgar","filing":"0001140361-21-032248","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036121032248/form4.xml","form_type":"4"}},{"id":2755986,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-06T13:00:35.000Z","date":"2021-04-05","kind":"purchase","acquired":true,"shares":5000,"price":2.04,"value":10200.0,"ownership":{"direct":false,"nature":"By a limited liability company controlled by the Reporting Person: Freeman Global Holdings, LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0000899243-21-015010","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924321015010/doc4.xml","form_type":"4"}},{"id":2769599,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-03-29T20:35:36.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Such options vest when (i) the Company has received the interim results of its NAVIGATE clinical trial and (ii) makes a public announcement that it has received the interim results."}],"balance_after":70000,"derivative":{"exercise_price":2.11,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0000899243-21-013818","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924321013818/doc4.xml","form_type":"4"}},{"id":2769598,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-03-29T20:35:36.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such options vest 100% on March 31, 2022."}],"balance_after":40000,"derivative":{"exercise_price":2.11,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-21-013818","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924321013818/doc4.xml","form_type":"4"}},{"id":3035662,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-09T12:00:26.000Z","date":"2020-09-04","kind":"purchase","acquired":true,"shares":5000,"price":2.5696,"value":12848.0,"ownership":{"direct":false,"nature":"By a limited liability company controlled by the Reporting Person: Freeman Global Holdings, LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0000899243-20-024607","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924320024607/doc4.xml","form_type":"4"}},{"id":3199545,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-20T12:30:26.000Z","date":"2020-03-19","kind":"purchase","acquired":true,"shares":6000,"price":1.6407,"value":9844.2,"ownership":{"direct":false,"nature":"By a limited liability company controlled by the Reporting Person: Freeman Global Holdings, LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0000899243-20-009061","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924320009061/doc4.xml","form_type":"4"}},{"id":3312689,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2020-01-13T23:02:14.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2020."}],"balance_after":45000,"derivative":{"exercise_price":2.86,"expiration_date":"2030-01-09","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000899243-20-001121","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924320001121/doc4.xml","form_type":"4"}},{"id":3368735,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-18T15:01:32.000Z","date":"2019-11-15","kind":"purchase","acquired":true,"shares":3000,"price":3.3586,"value":10075.8,"ownership":{"direct":false,"nature":"By a limited liability company controlled by the Reporting Person: Freeman Global Holdings, LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":14000,"source":{"system":"sec-edgar","filing":"0000899243-19-027471","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924319027471/doc4.xml","form_type":"4"}},{"id":3419702,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-09T17:30:33.000Z","date":"2019-09-06","kind":"purchase","acquired":true,"shares":1290,"price":3.71,"value":4785.9,"ownership":{"direct":false,"nature":"By a limited liability company wholly-owned by Freeman Global Holdings, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price, rounded to the nearest cent.  The shares were purchased in multiple transactions at prices ranging from $3.705 to $3.713 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased by the Reporting Person at each separate price on each date of purchase."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":11000,"source":{"system":"sec-edgar","filing":"0000899243-19-023102","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924319023102/doc4.xml","form_type":"4"}},{"id":3505070,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Purchase Warrant (right to buy)","published_at":"2019-06-03T21:31:51.000Z","date":"2019-05-31","kind":"purchase","acquired":true,"shares":25700,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By a limited liability company wholly-owned by Freeman Global Holdings, LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each warrant is exerciseable for 0.075 shares of Common Stock of the Company."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Each warrant is exerciseable for 0.075 shares of Common Stock of the Company."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":25700,"derivative":{"exercise_price":7,"exercise_date":"2019-11-30","expiration_date":"2026-05-31","underlying":"Common Stock","underlying_shares":1928},"source":{"system":"sec-edgar","filing":"0001179022-19-000035","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000035/edgar.xml","form_type":"4"}},{"id":3505069,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Purchase Warrant (right to buy)","published_at":"2019-06-03T21:31:51.000Z","date":"2019-05-31","kind":"purchase","acquired":true,"shares":4753,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each warrant is exerciseable for 0.075 shares of Common Stock of the Company."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Each warrant is exerciseable for 0.075 shares of Common Stock of the Company."}],"balance_after":4753,"derivative":{"exercise_price":7,"exercise_date":"2019-11-30","expiration_date":"2026-05-31","underlying":"Common Stock","underlying_shares":356},"source":{"system":"sec-edgar","filing":"0001179022-19-000035","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000035/edgar.xml","form_type":"4"}},{"id":3505068,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-03T21:31:51.000Z","date":"2019-05-31","kind":"purchase","acquired":true,"shares":1426,"price":4.28,"value":6103.28,"ownership":{"direct":true},"balance_after":23469,"source":{"system":"sec-edgar","filing":"0001179022-19-000035","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000035/edgar.xml","form_type":"4"}},{"id":3505067,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-03T21:31:51.000Z","date":"2019-05-31","kind":"purchase","acquired":true,"shares":7710,"price":4.28,"value":32998.8,"ownership":{"direct":false,"nature":"By a limited liability company wholly-owned by Freeman Global Holdings, LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":9710,"source":{"system":"sec-edgar","filing":"0001179022-19-000035","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000035/edgar.xml","form_type":"4"}},{"id":3560529,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-08T20:30:09.000Z","date":"2019-04-05","kind":"purchase","acquired":true,"shares":500,"price":4.73,"value":2365.0,"ownership":{"direct":false,"nature":"By a limited liability company wholly-owned by Freeman Global Holdings, LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001179022-19-000028","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000028/edgar.xml","form_type":"4"}},{"id":3666237,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-11T21:23:30.000Z","date":"2019-02-08","kind":"purchase","acquired":true,"shares":1500,"price":4.285,"value":6427.5,"ownership":{"direct":false,"nature":"By a limited liability company wholly-owned by Freeman Global Holdings, LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":1500,"source":{"system":"sec-edgar","filing":"0001179022-19-000025","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000025/edgar.xml","form_type":"4"}},{"id":3691958,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2019-01-18T22:18:11.000Z","date":"2019-01-16","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 100% on January 16, 2020."}],"balance_after":40000,"derivative":{"exercise_price":4.72,"expiration_date":"2029-01-16","underlying":"Common stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001179022-19-000013","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000013/edgar.xml","form_type":"4"}},{"id":4079555,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-02T13:57:14.000Z","date":"2018-02-01","kind":"purchase","acquired":true,"shares":2000,"price":4.0955,"value":8191.0,"ownership":{"direct":false,"nature":"IRA"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 6,000 shares that the reporting person previously mistakenly reported as being held directly and which should have been reported as being held indirectly, by the reporting person's IRA."}],"balance_after":16000,"source":{"system":"sec-edgar","filing":"0001179022-18-000013","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000013/edgar.xml","form_type":"4"}},{"id":4079552,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-02T13:25:50.000Z","date":"2018-02-01","kind":"purchase","acquired":true,"shares":2000,"price":4.0955,"value":8191.0,"ownership":{"direct":false,"nature":"IRA"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 6,000 shares that the reporting person previously mistakenly reported as being held directly and which should have been reported as being held indirectly, by the reporting person's IRA."}],"balance_after":16000,"source":{"system":"sec-edgar","filing":"0001179022-18-000012","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000012/edgar.xml","form_type":"4"}},{"id":4128831,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2017-12-18T21:12:43.000Z","date":"2017-12-14","kind":"grant","acquired":true,"shares":46875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 100% on December 14, 2018."}],"balance_after":46875,"derivative":{"exercise_price":2.39,"expiration_date":"2027-12-14","underlying":"Common stock","underlying_shares":46875},"source":{"system":"sec-edgar","filing":"0001179022-17-000079","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902217000079/edgar.xml","form_type":"4"}},{"id":4138104,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-08T19:26:42.000Z","date":"2017-12-07","kind":"purchase","acquired":true,"shares":400,"price":1.6433,"value":657.32,"ownership":{"direct":true},"balance_after":28043,"source":{"system":"sec-edgar","filing":"0001179022-17-000070","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902217000070/edgar.xml","form_type":"4"}},{"id":4138103,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-08T19:26:42.000Z","date":"2017-12-07","kind":"purchase","acquired":true,"shares":8000,"price":1.6256,"value":13004.8,"ownership":{"direct":false,"nature":"IRA"},"balance_after":8000,"source":{"system":"sec-edgar","filing":"0001179022-17-000070","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902217000070/edgar.xml","form_type":"4"}},{"id":4517221,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69096,"kind":"person","name":"FREEMAN KEVIN D","position":1,"cik":"0001522478","reported_name":"FREEMAN KEVIN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2016-12-19T21:28:12.000Z","date":"2016-12-15","kind":"grant","acquired":true,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 100% on the date of Galectin Therapeutics, Inc.'s 2017 Annual Stockholders Meeting."}],"balance_after":31250,"derivative":{"exercise_price":0.89,"expiration_date":"2026-12-15","underlying":"Common stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0001179022-16-000136","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902216000136/edgar.xml","form_type":"4"}}]}